Drug Type Small molecule drug |
Synonyms Pelubi, Pelubiprofen (JAN/INN), 培比洛芬 + [8] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (01 Dec 2008), |
Regulation- |
Molecular FormulaC16H18O3 |
InChIKeyAUZUGWXLBGZUPP-GXDHUFHOSA-N |
CAS Registry69956-77-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Back Pain | KR | 01 Dec 2008 | |
Osteoarthritis | KR | 01 Dec 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary dysmenorrhea | Phase 3 | - | 30 Sep 2020 | |
Wounds and Injuries | Phase 3 | KR | 25 Feb 2019 | |
Acute upper respiratory infection | Phase 3 | KR | 01 Jan 2013 | |
Fever | Phase 3 | KR | 01 Jan 2013 | |
Rheumatoid Arthritis | Phase 3 | - | 01 Oct 2010 | |
Acute Pain | Phase 3 | KR | - | |
Rheumatic Diseases | Phase 3 | US | - | |
Rheumatic Diseases | Phase 3 | JP | - | |
Low Back Pain | Phase 1 | CN | 30 Jan 2023 | |
Low Back Pain | Phase 1 | CN | 30 Jan 2023 |